Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis

Liu, Zhuang; Li, Junnan; Ji, Shibo; Li, Yue; Zhao, Yingying; Li, Ben; Li, Wei; Quan, Min; Duan, Ying; Zhao, Hong; Cheng, Danying; Wang, Xiaomei; Ou, Weini; Xing, Huichun

doi:10.1016/j.aohep.2020.09.012

Cited by 11 publications

(8 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SOF/LDV SVR rate was 97% compared to 100% of SOF/VEL in GT6 after 12 wk of treatment[ 96 , 97 ]. In a meta-analysis of 34 studies, SOF/DCV, SOF/VEL, SOF/VEL/ voxilaprevir and GLE/PIB were found to have similar SVRs in both non-cirrhotic (95.24%) and cirrhotic (89.39%) patients[ 98 ]. Better results for SOF/LDV compared to SOF/VEL were reported in PWID[ 99 , 100 ].…”

Section: Can We Eradicate Hcv By 2030 With Daas Treatment?mentioning

confidence: 99%

Hepatitis C virus: A critical approach to who really needs treatment

Voumvouraki¹

2022

WJH

View full text Add to dashboard Cite

Introduction of effective drugs in the treatment of hepatitis C virus (HCV) infection has prompted the World Health Organization to declare a global eradication target by 2030. Propositions have been made to screen the general population and treat all HCV carriers irrespective of the disease status. A year ago the new severe acute respiratory syndrome coronavirus 2 virus appeared causing a worldwide pandemic of coronavirus disease 2019 disease. Huge financial resources were redirected, and the pandemic became the first priority in every country. In this review, we examined the feasibility of the World Health Organization elimination program and the actual natural course of HCV infection. We also identified and analyzed certain comorbidity factors that may aggravate the progress of HCV and some marginalized subpopulations with characteristics favoring HCV dissemination. Alcohol consumption, HIV coinfection and the presence of components of metabolic syndrome including obesity, hyperuricemia and overt diabetes were comorbidities mostly responsible for increased liver-related morbidity and mortality of HCV. We also examined the significance of special subpopulations like people who inject drugs and males having sex with males. Finally, we proposed a different micro-elimination screening and treatment program that can be implemented in all countries irrespective of income. We suggest that screening and treatment of HCV carriers should be limited only in these particular groups.

show abstract

Section: Can We Eradicate Hcv By 2030 With Daas Treatment?mentioning

confidence: 99%

Hepatitis C virus: A critical approach to who really needs treatment

Voumvouraki¹

2022

WJH

View full text Add to dashboard Cite

show abstract

“…A study compared full-length HCV sequence from patients with or without HCC using a logistic regression model identified 7 polymorphisms, including the codon for amino acid 70 in HCV core protein sequence, significantly associated with increased HCC risk [ 72 ]. In the cases of DAA treatments, different SVR rates of the treatments are found to associate with different HCV genotypes [ 80 81 82 83 ]. HCV genotype 3 seems to be more resistant to DAA treatments [ 83 ].…”

Section: H Epatitis C Virus Core Protein...mentioning

confidence: 99%

“…In the cases of DAA treatments, different SVR rates of the treatments are found to associate with different HCV genotypes [ 80 81 82 83 ]. HCV genotype 3 seems to be more resistant to DAA treatments [ 83 ]. The direct roles played by core protein viability in DAA resistance have not yet been identified.…”

Section: H Epatitis C Virus Core Protein...mentioning

confidence: 99%

Hepatitis C virus core protein: Not just a nucleocapsid building block, but an immunity and inflammation modulator

et al. 2022

View full text Add to dashboard Cite

Coevolution occurs between viruses and their hosts. The hosts need to evolve means to eliminate pathogenic virus infections, and the viruses, for their own survival and multiplication, have to develop mechanisms to escape clearance by hosts. Hepatitis C virus (HCV) of Flaviviridae is a pathogen which infects human liver and causes hepatitis, a condition of liver inflammation. Unlike most of the other flaviviruses, HCV has an excellent ability to evade host immunity to establish chronic infection. The persistent liver infection leads to chronic hepatitis, liver cirrhosis, hepatocellular carcinoma (HCC), as well as extrahepatic HCV-related diseases. HCV genomic RNA only expresses 10 proteins, many of which bear functions, in addition to those involved in HCV life cycle, for assisting the virus to develop its persistency. HCV core protein is a structural protein which encapsulates HCV genomic RNA and assembles into nucleocapsids. The core protein is also found to exert functions to affect host inflammation and immune responses by altering a variety of host pathways. This paper reviews the studies regarding the HCV core protein-induced alterations of host immunity and inflammatory responses, as well as the involvements of the HCV core protein in pro- and anti-inflammatory cytokine stimulations, host cellular transcription, lipid metabolism, cell apoptosis, cell proliferations, immune cell differentiations, oxidative stress, and hepatocyte steatosis, which leads to liver fibrosis, cirrhosis, and HCC. Implications of roles played by the HCV core protein in therapeutic resistance are also discussed.

show abstract

“…Velpatasvir (VLP) is a direct-acting NS5A inhibitor, a generic product Epclusa in combination with sofosbuvir, that is used for the pan-genotypic treatment of chronic hepatitis C viral (HCV) infection. − In addition, Epclusa was found to possess a high potential of SARS-COV-2 inhibition. − HCV is a ribonucleic acid virus discovered in 1989, which is the most common predisposing factor for chronic liver disease, liver cirrhosis, and liver cancer in addition to liver transplant surgery in the US and many other countries around the world. − In 2016, EpclusaVLP in combination with sofosbuvir (a single 12 week regimen tablet for all HCV genotypes)was proposed as a revolutionary treatment of HCV complicated and non-complicated patients. , This makes the greatest turnover in this century in HCV prognosis, providing the best sustained viral response among other combinations of direct-acting antiviral agents (DAAAs) by achieving 99% sustained viral response decompensated cirrhotic patients in a 12 week regimen. , On the other hand, using molecular docking analyses, Epclusa has shown to exhibit high efficiency against COVID-19. , This was ascribed to the similarity between nonstructural protein 12 (nsp12) in both HCV and SARS-COV-2 RNA polymerases, which was found to possess high potential for SARS-COV-2 viral infection. , …”

Section: Introductionmentioning

confidence: 99%

Sensitive Determination of SARS-COV-2 and the Anti-hepatitis C Virus Agent Velpatasvir Enabled by Novel Metal–Organic Frameworks

et al. 2021

View full text Add to dashboard Cite

Herein, we report on the electrochemical determination of velpatasvir (VLP) as the main constituent of Epclusa, a SARS-COV-2 and anti-hepatitis C virus (HCV) agent, using a novel metal–organic framework (MOF). The NH2-MIL-53(Al) MOF was successfully modified with 5-bromo-salicylaldehyde to synthesize 5-BSA=N-MIL-53(Al) MOF. The synthesized MOF has been characterized using Fourier transform infrared spectroscopy, X-ray powder diffraction, scanning electron microscopy, cyclic voltammetry, square wave voltammetry, and electrochemical impedance spectroscopy. The modified MOF showed higher electrochemical activity and response than the bare NH2-MIL-53(Al) MOF. Compared to the bare carbon paste electrode (CPE), the 5-BSA=N-MIL-53(Al)/CPE platform was shown to enhance the electrochemical oxidation and detection of the anti-SARS-COV-2 and anti-HCV agent. Under optimized conditions, the 5-BSA=N-MIL-53(Al)/CPE platform showed a linear range of 1.11 × 10–6 to 1.11 × 10–7 and 1.11 × 10–7 to 25.97 × 10–6 M Britton–Robinson buffer (pH 7) with a detection limit and limit of quantification of 8.776 × 10–9 and 2.924 × 10–8 M, respectively. Repeatability, storage stability, and reproducibility in addition to selectivity studies and interference studies were conducted to illustrate the superiority of the electrode material. The study also included a highly accurate platform for the determination of VLP concentrations in both urine and plasma samples with reasonable recovery.

show abstract

Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis

Cited by 11 publications

References 43 publications

Hepatitis C virus: A critical approach to who really needs treatment

Hepatitis C virus: A critical approach to who really needs treatment

Hepatitis C virus core protein: Not just a nucleocapsid building block, but an immunity and inflammation modulator

Sensitive Determination of SARS-COV-2 and the Anti-hepatitis C Virus Agent Velpatasvir Enabled by Novel Metal–Organic Frameworks

Contact Info

Product

Resources

About